SCHEMBL3765680

SCHEMBL3765680

Cc1noc(NC(=O)N2CCN(c3nc(-c4ccccc4)ns3)CC2)c1C

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FAAH O00519 18/20 0.73
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766291 0.90 FAAH (0.74) FAAH
SCHEMBL3765815 0.90 FAAH (0.68) FAAHNPC1RAB9A
SCHEMBL3767632 0.89 FAAH (0.75) FAAHRAB9A
SCHEMBL3777232 0.87 FAAH (0.76) FAAH
SCHEMBL3765774 0.86 FAAH (0.76) FAAHNPC1RAB9A
SCHEMBL3765775 0.86 FAAH (0.54) FAAHRAB9A
SCHEMBL3772447 0.83 FAAH (0.72) FAAHNPC1RAB9A
SCHEMBL3778588 0.82 AR (0.52) FAAH
SCHEMBL3769724 0.82 FAAH (0.73) FAAHNPC1RAB9A
SCHEMBL3764401 0.82 FAAH (0.70) FAAHNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 FAAH 1/4885NPC1 1078/4885RAB9A 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.